Zusammenfassung
Die Behandlung der unterschiedlichen Osteoporoseformen durch Bisphosphonate hat sich als sichere und effektive Therapie erwiesen. In den letzten Jahren wurde allerdings über seltene unerwünschte Komplikationen in der Langzeitbehandlung berichtet. Insbesondere das Auftreten atypischer subtrochantärer Frakturen rückte zunehmend in den klinischen Fokus. Dennoch fand diese Problematik kaum Berücksichtigung in der wissenschaftlichen Diskussion. Anhand eines Fallberichts und Darstellung des aktuellen Literaturstandes soll diese Thematik mit dem Ziel einer früheren Diagnosestellung und Therapie dieser Komplikation aufgegriffen werden.
Abstract
During the last several years the treatment of osteoporosis with bisphosphonates has become accepted as a safe and effective procedure. However, recently there have been increasing numbers of reports of rare complications in the literature. Particularly the occurrence of atypical fractures of the femur has become a focus of interest but the problem is insufficiently known and only rarely addressed in the scientific discussion. The case illustrated here and a survey of the important facts in the recent literature highlight essential aspects of long-term bisphosphonate therapy.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Black D, Cummings S, Karpf D (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541
Bone H, Hosking D, Devogelaer J (2004) Ten years‘ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199
S3-Leitlinie Osteoporose. Dachverband Osteologie eV (DVO). http://www.dv-osteologie.org 2009
Rogers M, Brown R, Hodkin V et al (1996) Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224:863–869
Luckman S, Hughes D, Coxon F (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Mineral Res 13:581–589
Watts N, Diab D (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565
Abrahamsen B (2010) Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol 22:404–409
Otto S, Abu-Id M, Fedele S et al (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence – a multi-centre study. J Craniomaxillofac Surg 39:272–277
Koh J, Goh S, Png M et al (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture. J Orthop Trauma 24:75–81
Kwek E, Goh S, Koh J et al (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231
Black D, Kelly M, Genant H et al (2010) Bisphosphonates an fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771
Russell R, Watts N, Ebetino F, Rogers M (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759
Odvina C, Zerwekh J, Rao D et al (2005) Severely suppressed bone turnover: potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301
Armamento-Villareal R, Napoli N, Diemer K et al (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures recieving bisphosphonates: a case series. Calcif Tissue Int 85:37–44
Currey J (1984) Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 304:509–518
Richer E, Lewis M, Odvina C et al (2005) Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int 16:1384–1392
Mashiba T, Mori S, Burr D (2005) The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23:36–42
Mashiba T, Turner C, Hirano T (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531
Ciarelli T, Fyhrie D, Parfitt A (2003) Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 32:311–315
Boivin G, Chavassieux P, Santora A et al (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694
Chaiamnuay S, Saag K (2006) Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 7:101–112
Boonen S, Laan R, Barton I, Watts N (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291–1298
Lo J, O’Ryan F, Gordon N et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253
Ensrud K, Black D, Palermo L et al (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157:2617–2624
Goddard M, Reid K, Johnston J, Khanuja H (2009) Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 32:607
Pauwels F (1948) Die Bedeutung der Bauprinzipien des Stütz- und Bewegungsapparates für die Beanspruchung langer Röhrenknochen. Z Anat 114:129–166
Breglia M, Carter J (2010) Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol 16:76–78
Neviaser A, Lane J, Lenart B et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350
Lenart B, Lorich D, Lane J (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306
Bamrungsong T, Pongchaiyakul C (2010) Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. J Med Assoc Thai 93:620–624
Capeci C, Tejwani N (2009) Bilateral low-energy simultaneous or sequential femoral fractures. J Bone Joint Surg [Am] 91:2556–2561
Goh S, Yang K, Koh J (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg [Br] 89:349–353
Visekruna M, Wilson D, McKiernan F (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952
Schwartz A, Bauer D, Cummings S et al (2010) Efficacy of continued alendronate for fractures in women with and without prevalent fracture: the FLEX trial. J Bone Min Res 25:976–982
Giusti A, Hamdy N, Papapoulos S (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47:169–180
Sayed-Noor A, Sjödén G (2009) Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 467:1921–1926
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lenz, R., Ellenrieder, M., Skripitz, R. et al. Bisphosphonatinduzierte Stressfrakturen am Femur. Orthopäde 40, 1111–1118 (2011). https://doi.org/10.1007/s00132-011-1786-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00132-011-1786-6